Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Insider Sells $17,757.85 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) insider Dennis Karl Huang sold 389 shares of the stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $45.65, for a total value of $17,757.85. Following the completion of the sale, the insider now directly owns 75,314 shares in the company, valued at approximately $3,438,084.10. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Ultragenyx Pharmaceutical Stock Up 1.4 %

NASDAQ:RARE opened at $45.70 on Monday. The stock’s 50 day moving average price is $44.59 and its 200 day moving average price is $42.63. The company has a market capitalization of $3.21 billion, a PE ratio of -4.52 and a beta of 0.94. Ultragenyx Pharmaceutical Inc. has a 52-week low of $33.36 and a 52-week high of $85.53.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last released its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported ($2.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.13). Ultragenyx Pharmaceutical had a negative return on equity of 110.15% and a negative net margin of 194.71%. The firm had revenue of $103.35 million for the quarter, compared to analysts’ expectations of $105.11 million. During the same quarter in the prior year, the business earned ($1.79) EPS. The company’s quarterly revenue was up 23.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -7.62 EPS for the current fiscal year.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its position in Ultragenyx Pharmaceutical by 151.0% during the 3rd quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 361 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $27,000. Lazard Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 36.6% during the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 240 shares during the period. Quadrant Capital Group LLC lifted its position in Ultragenyx Pharmaceutical by 111.4% during the 4th quarter. Quadrant Capital Group LLC now owns 924 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 487 shares during the period. Finally, High Net Worth Advisory Group LLC lifted its position in Ultragenyx Pharmaceutical by 650.0% during the 3rd quarter. High Net Worth Advisory Group LLC now owns 1,500 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 1,300 shares during the period. 93.17% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on RARE. Morgan Stanley reduced their price target on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, February 3rd. Credit Suisse Group reiterated an “outperform” rating and issued a $96.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 17th. StockNews.com upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, February 23rd. Robert W. Baird increased their price objective on Ultragenyx Pharmaceutical from $50.00 to $57.00 and gave the company an “outperform” rating in a report on Friday, February 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $82.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, December 30th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $89.47.

Ultragenyx Pharmaceutical Company Profile

(Get Rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.